Advanced breast cancer in women w/ natural or induced postmenopausal status whose disease has progressed following antiestrogen therapy. Patient selection should be based on +ve oestrogen &/or progesterone receptor status, because efficacy has not been demonstrated when it is absent. Adjuvant treatment of postmenopausal women w/ estrogen-receptor +ve early breast cancer, following 2-3 yr of initial adjuvant tamoxifen therapy.
Adult & elderly 25 mg once daily. Patient w/ early breast cancer Continue until completion of 5 yr of adjuvant endocrine therapy or until local or distant recurrence or new contralateral breast cancer. Patient w/ advanced breast cancer Continue until tumor progression is evident.
Not for women w/ premenopausal endocrine status. Postmenopausal status ascertained by assessment of LH, FSH & oestradiol levels. Assess bone mineral density in women w/ osteoporosis or at risk of osteoporosis. Reduction of bone mineral density. Consider routine assessment of 25 hydroxy vit D levels prior to start of aromatase inhibitor treatment. Supplementation of vit D in women w/ vit D deficiency. Hepatic or renal impairment. May impair ability to drive or operate machinery. Childn.
Sign Out
